Home
About
Overview
Sharing Data
ORCID
Help
History (7)
Point mutations in domain III of a Drosophila neuronal Na channel confer resistance to allethrin.
Pulmonary Atelectasis
Single sample expression-anchored mechanisms predict survival in head and neck cancer.
Urological Agents
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.
See All 7 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012 Aug 15; 72(16):3928-37.
View in:
PubMed
subject areas
Animals
Combined Modality Therapy
Female
Humans
Immunotherapy, Adoptive
Indoles
Lymphocyte Activation
Male
Melanoma
Melanoma, Experimental
Mice
Mice, Inbred C57BL
Mice, Transgenic
Protein Kinase Inhibitors
Proto-Oncogene Proteins B-raf
Sulfonamides
T-Lymphocytes
Tumor Cells, Cultured
authors with profiles
Thinle Chodon
Richard Koya